肿瘤学先进血管通路解决方案提供商Portal Access宣布完成700万美元A轮融资，以支持下一代化疗端口的FDA批准和有限市场发布-动脉网

Portal Access, Inc. Announces the closing of $7 Million Series A Financing Round to Support FDA Approval and Limited Market Launch of Next-Generation Chemotherapy Port

CISION 等信源发布 2025-05-28 07:28



可切换为仅中文







MIAMI

迈阿密

，

May 27, 2025

2025年5月27日

/PRNewswire/ -- Portal Access, Inc., a medical device start-up company pioneering next-generation advanced vascular access solutions for oncology, announced the successful closing of a

/PRNewswire/ -- Portal Access, Inc.是一家开创下一代先进血管通路解决方案的医疗设备初创公司，专注于肿瘤学领域，宣布成功完成了

$7 million

700万美元

Series A financing round today. The round was fully subscribed, reflecting strong investor support for the company's vision and technology. Over 80% of the round was led by U.S physician investors including oncologists, interventional radiologists, cardiologists, vascular surgeons and others, in addition to a partnership from a U.S based venture capital fund; underscoring strong clinical conviction and belief in the device's potential to modernize cancer care drug delivery..

今天完成了A轮融资。本轮资金已全额认购，反映了投资者对公司愿景和技术的强烈支持。超过80%的资金来自美国的医生投资者，包括肿瘤学家、介入放射科医生、心脏病学家、血管外科医生等，此外还有一家美国风险投资基金的合作；这凸显了对其设备在现代化癌症治疗药物递送方面潜力的高度临床认可和信心。

The funds will support regulatory activities and the planned 510(k) submission for approval to the U.S. Food and Drug Administration (FDA) for Flexi-Port

这笔资金将用于支持监管活动，并计划向美国食品和药物管理局 (FDA) 提交 510(k) 申请以获得 Flexi-Port 的批准。

™

SLF-TANL

™

, a novel subcutaneous port designed to simplify vascular access for oncology patients and a limited market launch. 510(k) submission is expected

，一种新型的皮下端口，旨在简化肿瘤患者的血管通路，并进行有限的市场投放。预计将会提交510(k)申请。

July 2025

2025年7月

and U.S market launch is anticipated in early 2026. The device is intended to enhance usability, reduce complexity, broaden accessibility and decrease costs.

预计将在2026年初进入美国市场。该设备旨在提高可用性、降低复杂性、扩大可及性并降低成本。

Dr.

博士

Michael Tal

迈克尔·塔尔

, Founder and CEO of PorTal Access Inc. says 'Closing this funding round represents an important milestone as we work toward regulatory approval. Flexi-Port

PorTal Access Inc.创始人兼首席执行官表示：“完成本轮资金募集代表了我们在争取监管批准过程中的一个重要里程碑。Flexi-Port

™

SLF-TANL

™

is engineered with a focus on simplicity, stability, and scalability — likely to support more efficient workflows in oncology access settings. It's a solution for both clinicians and patients and created with the most optimal patient outcome and experience in mind.'

该系统以简洁、稳定和可扩展性为重点进行设计，有望在肿瘤学应用环境中支持更高效的工作流程。它是一个面向临床医生和患者的解决方案，旨在实现最佳的患者治疗效果和体验。

Despite being the standard of care, it is estimated that nearly half of cancer patients do not receive a chemo-port due to various reasons like delay in treatment. By simplifying access and potentially enabling placement in additional care settings, The Flexi-Port

尽管这是护理的标准做法，但据估计，由于治疗延迟等各种原因，近一半的癌症患者并未接受化疗端口。通过简化获取途径并可能在更多的护理环境中实现植入，The Flexi-Port

™

SLF-TANL

™

device may help reduce treatment delays, procedural risks, and overall healthcare costs — improving the patient experience and operational efficiency across cancer care delivery.

设备有助于减少治疗延误、程序风险和总体医疗成本，改善患者体验，并提高癌症诊疗全过程的运营效率。

'I have used the Flexi-Port SLF-TANL to provide chemotherapy in some of the most vulnerable patients and it has consistently exceeded expectations,' says

“我使用 Flexi-Port SLF-TANL 为一些最脆弱的患者提供化疗，结果始终超出预期，”

Matthew Ostroff, RN

马修·奥斯特罗夫，注册护士

, MSN, AGACNP, VABC, a pioneer in the field of bedside vascular access. 'Its innovative self-tunneling technology is a revolutionary advancement offering a less invasive option that can be placed safely at the bedside or in an outpatient setting. From a clinical perspective, this technology has the potential to transform the standard of care in port placement – offering patients a more dignified, convenient, and compassionate experience at a time when it matters most.'.

，MSN，AGACNP，VABC，床旁血管通路领域的先驱。“其创新的自隧道技术是一项革命性的进步，提供了一种侵入性更小的选择，可以安全地在床旁或门诊环境中放置。从临床角度来看，这项技术有潜力改变输液港放置的标准——在最紧要的时刻为患者提供更有尊严、更方便和更富有同情心的体验。”

Angela Dotson

安吉拉·多森

, Executive VP of Business Development at PorTal Access, Inc. said, 'In my career, I have never witnessed this level of enthusiasm from physicians for a medical technology. During our Series A round, the demand for the Flexi-Port

Portal Access公司业务发展执行副总裁说：“在我的职业生涯中，我从未见过医生对一项医疗技术有如此高的热情。在我们进行A轮融资期间，对Flexi-Port的需求量很大。”

™

SLF-TANL

™

was overwhelming—$6 million of our funding came directly from individual physician investors. This type of physician-driven investment is both remarkable and virtually unprecedented. From a market development perspective, the response has been equally compelling. We are seeing significant interest from clinics and hospitals across the country, many of which are already preparing to integrate the Flexi-Port.

十分惊人——我们的600万美元资金直接来自于个体医生投资者。这种由医生推动的投资既引人注目，又几乎是前所未有的。从市场发展的角度来看，反响同样令人信服。我们看到全国各地的诊所和医院都表现出极大的兴趣，其中许多机构已经在准备整合Flexi-Port。

™

SLF-TANL

™

into their practice as soon as it becomes available. They've been waiting more than 30 years for an innovation like this. Today, we are one step closer to delivering this transformative solution to clinicians and their patients.'

一旦可用，就会将其投入应用。他们已经等待了30多年这样的创新。今天，我们离将这一变革性解决方案交付给临床医生和患者更近了一步。

About PorTal Access, Inc.:

关于PorTal Access公司：

PorTal Access, Inc. is committed to designing solutions that aim to reduce complications currently associated with chemo port placement while offering a safe and minimally invasive option for bedside or in an outpatient setting. Flexi-Port

PorTal Access, Inc. 致力于设计旨在减少当前与化疗端口放置相关并发症的解决方案，同时提供一种安全且微创的床边或门诊选择。Flexi-Port

™

商标符号

SLF-TANL

™

is currently not available for sale.

目前无法销售。

For more information or to be added to our market launch, please contact:

如需更多信息或希望加入我们的市场发布，请联系：

Angela Dotson

安吉拉·多森

Executive VP Business Development